BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-791@pharmaconomics
DTSTAMP:20260707T034714Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IRD Phase 3 — OPGx-LCA5 (estimated date)
DESCRIPTION:Phase 3 trial results for OPGx-LCA5 in Leber Congenital Amaurosis (LCA) due to biallelic mutations in the LCA5 gene are due ~ Dec 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1228627/000114036126000615/ef20062523_ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/791
URL:https://www.pharmaconomics.com/e/791
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IRD catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR